A US federal court said this week it will allow 10x Genomics to provide Vanderbilt University’s Vaccine Center with a new Chromium instrument configured to run GEM microfluidic chips to help respond to the 2019-nCoV coronavirus outbreak. 10x Genomics has been prohibited from selling so-called legacy instruments under an injunction issued by the US District Court for the District of Delaware, but the firm has been granted a one-time exception. Bio-Rad Laboratories, the plaintiff in the patent infringement suit that led to the injunction, agreed to the arrangement. Vanderbilt’s Vaccine Center requested the instrument to run 10x’s single-cell immune profiling assay on control samples, after it moved its existing Chromium instrument into a contained environment.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.